The STAT3 (Signal Transducer and Activator of Transcription 3) pathway is a central hub for cell growth, survival, and differentiation. Activated by key cytokines—primarily IL-6, OSM, and IL-11—STAT3 undergoes phosphorylation, forms homodimers or STAT1 heterodimers, and translocates to the nucleus. Once there, it binds to specific consensus elements to drive the expression of genes associated with oncogenesis and immune response.

​

Signosis offers a suite of robust, pre-validated stable cell lines designed to monitor STAT3 transcriptional activity in real-time. By integrating a luciferase reporter regulated by four tandem repeats of the STAT3 binding site, these lines eliminate the need for tedious transient transfections and provide a reliable window into the JAK/STAT cascade.

​

​

Why Focus on IL-6 and IL-11 Pathways?

Our STAT3 reporter lines are optimized to respond to the two most clinically relevant branches of STAT3 signaling:

• The IL-6/OSM Axis: IL-6 is the canonical activator of STAT3. It is a primary driver of chronic inflammation and the "cytokine storm." Our lines (HEK293, HeLa, K562, and HepG2) are specifically screened for high induction in response to IL-6 and Oncostatin M, making them ideal for studying inflammatory diseases and solid tumor progression.

• The IL-11 Axis: IL-11 is increasingly recognized for its role in fibrosis and epithelial-to-mesenchymal transition (EMT). Our specialized STAT3-HEK293 (IL-11 responsive) line provides a dedicated tool for researchers investigating IL-11’s unique role in tissue regeneration and fibrotic signaling.